Category Archives: Uncategorized

RCEP negotiators must fix the damaging provisions that remain a threat to public health

Hyderabad, July 21, 2017 – As negotiators for the Regional Comprehensive Economic Partnership (RCEP) trade agreement meet for another round of negotiations in Hyderabad next week, networks of people living with HIV/AIDS  from different parts of the country, public health experts from the … Continue reading

Posted in Data Exclusivity, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, Uncategorized | Leave a comment

Escaping Big Pharma’s Pricing With Patent-Free Drugs

Source: New York Times How’s this for a great deal? The United States government funded research and development of a new vaccine against Zika. But the Army, which paid a French pharmaceutical manufacturer for its development, is planning to grant exclusive … Continue reading

Posted in Uncategorized, R&D, Patent | Leave a comment

An Access Regime based on Indian Patents Act -Review Of “The Access Regime” by Feroz Ali

Source: LiveLaw.in Even though the Agreement on the trade-related aspects of intellectual property rights (TRIPS) set the minimum standards of protection and enforcement of intellectual property (IP) rights, it could not harmonise the various national patent laws. Irrespective of the … Continue reading

Posted in Compulsory Licensing, FTA, Patent Opposition, Sec 3 (d), TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

COLD RECEPTION TO RCEP AS PEOPLE’S RESISTANCE CONSOLIDATES

July 19,  2017 | New Delhi, India Released at the Press Club of India On July 18, 2017 the 19th round of RCEP (Regional Comprehensive Economic Partnership) negotiations began in Hyderabad. While the subject-wise Working Groups formed under the RCEP … Continue reading

Posted in FTA, Regional Comprehensive Economic Partnership, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

Company sues Ukraine in bid to corner hepatitis C drug market

By Josh Kovensky, KyivPost | June 16, 2017 A doctor checks a patient for Hepatitis C in Zaporizhiya. As much as 10 percent of the Ukrainian population could be infected with the disease. Photo by UNIAN Multinational pharmaceutical firm Gilead Sciences has … Continue reading

Posted in Data Exclusivity, ISDS, Uncategorized | Leave a comment

Government should release Philip Morris plain packaging case costs says Fair Trade group

Media Release | July 10, 2017 “We welcome the international tribunal decision that Philip Morris tobacco company should pay the costs of its failed case against Australia’s 2011 plain packaging law. But it is absurd and unacceptable that the tribunal has … Continue reading

Posted in BITS, Investment treaties, ISDS, Uncategorized | Leave a comment

Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union: A proposal for greater coherence in European pharmaceutical legislation

Ellen ‘t Hoen, Pascale Boulet & Brook K. Baker Source: 10 J. Pharmaceutical Policy & Practice (June 2017) DOI 10.1186/s40545-017-0107-9, https://joppp.biomedcentral.com/track/pdf/10.1186/s40545-017-0107-9?site=joppp.biomedcentral.com Abstract The challenge of providing access to high-priced patented medicines is a global problem affecting all countries. A decade and … Continue reading

Posted in Uncategorized | Leave a comment